Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
ImmunoScape logo — Transforming Cancer Therapy with Our Novel Seed-and-Boost Ap...

ImmunoScape

Transforming Cancer Therapy with Our Novel Seed-and-Boost Approach

Founded 2016 Singapore Singapore 22 employees Unknown Total: $41.25M Biotechnology, Life Sciences

General Information

Company Name ImmunoScape
Founded Year 2016
Location Singapore Singapore +2
Founders / Decision Makers
Team member
Employees 22
Industries Biotechnology, Life Sciences
Funding Stage Unknown
Social

Get notified when ImmunoScape moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About ImmunoScape

ImmunoScape, founded in 2016 and headquartered in Singapore, is at the forefront of innovating cancer therapy within the Biotechnology and Life Sciences industries. Their slogan, "Transforming Cancer Therapy with Our Novel Seed-and-Boost Approach," encapsulates their mission.

The company pioneers a mix of proprietary TCR T cells with validated Immuno-STAT T cell engagers, remedying current therapy limitations by enhancing in vivo expansion of tumor-targeting T-cells. This integration promises safer, more effective cancer therapies and improved patient experiences. ImmunoScape is actively progressing with IND-enabling studies, with a focus on swift clinical trial initiation.

Their ability to transform cell therapy has attracted notable investment interest, highlighted by an early VC round backed by EDBI as of 01 June 2025. ImmunoScape stands out for investors seeking impactful advancements in cancer treatment.

Taxonomy: Cancer Therapy, Seed-and-Boost Approach, TCR T Cells, Immuno-STAT T Cell Engagers, Cell Therapy, In Vivo Expansion, IND-Enabling Studies, Immune Profiling, Deep Immunomics Platform, Mass Cytometry, Single Cell Sequencing, Bioinformatics, Oncology, Immunotherapy, Immunomics

Services & Products

Development of novel cancer therapies
Personalized treatment approaches
Research and development in oncology

Target Customers

Healthcare professionals Oncologists Biotechnology researchers

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Early VC •••••• 1
Investor
01 Jun 2025
Grant •••••• 1 •••• •••• 01 Sep 2024
Early VC •••••• 3
Investor Investor Investor
01 Sep 2022
Early VC •••••• 3
Investor Investor Investor
01 Apr 2021
Early VC •••••• 2
Investor Investor
01 Aug 2020

View All 6 Funding Rounds

ImmunoScape Alternatives & Competitors

ImmunoScape vs
Gamida Cell Ltd.
Gamida Cell Ltd. United States

Working to turn cells into powerful therapeutics for patients with cancer.

Post Ipo Debt
93 employees
Biotechnology, Health Care
Compare ImmunoScape vs Gamida Cell Ltd.
ImmunoScape vs
Lyell Immunopharma
Lyell Immunopharma United States

At Lyell, we are advancing next-generation CAR T-cell product candidates for patients with cancer.

Unknown
229 employees
Biotechnology
ImmunoScape vs
Kite Pharma
Kite Pharma United States

At Kite, a Gilead Company, our singular focus is cell therapy to treat and cure cancer.

Acquired
4013 employees
Biotechnology, Health Care

FAQ About ImmunoScape

Transforming Cancer Therapy with Our Novel Seed-and-Boost Approach
ImmunoScape was founded in 2016.
ImmunoScape is headquartered in Singapore.
ImmunoScape operates in the following industries: Biotechnology, Life Sciences.
ImmunoScape has approximately 22 employees.
ImmunoScape has completed 6 funding rounds, raising a total of $41.25M. The latest funding stage is Unknown.
ImmunoScape offers: Development of novel cancer therapies, Personalized treatment approaches, Research and development in oncology.
Top alternatives and competitors to ImmunoScape include Gamida Cell Ltd., Lyell Immunopharma, Kite Pharma, CytoSeek, Alliance for Cancer Gene Therapy. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ImmunoScape and Gamida Cell Ltd. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors ImmunoScape and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy